FAQs
1. How do I know if precision medicine is right for me?
Many patients wonder whether precision medicine can benefit their specific condition. Typically, it is most applicable in diseases with known genetic components (like certain cancers, rare diseases, or pharmacogenomics-guided drug choices). Your healthcare provider can help determine if genetic testing or personalized approaches are suitable for your case.
2. Is genetic testing safe and accurate?
Genetic tests used in precision medicine are generally safe, involving simple blood or saliva samples. Accuracy depends on the type of test and the laboratory performing it. It’s important to use certified labs and discuss results with qualified healthcare professionals to understand implications fully.
3. Will my genetic information remain private?
Privacy concerns are common. Laws like HIPAA (in the U.S.) protect medical information, but genetic data requires special safeguards to prevent misuse or discrimination. Always inquire about data protection policies before undergoing testing.
4. Can precision medicine help with common diseases like diabetes or hypertension?
While precision medicine is more established in cancer and rare diseases, research is ongoing to apply it to common chronic conditions. Personalized lifestyle and medication plans based on genetic and environmental factors are emerging but not yet routine.
Reference
1. Kosorok, M. R., & Laber, E. B. (2019). Precision medicine. Annual review of statistics and its application, 6(1), 263-286.
2. Khodadadian, A., Darzi, S., Haghi-Daredeh, S., et al. (2020). Genomics and transcriptomics: the powerful technologies in precision medicine. International Journal of General Medicine, 627-640.
3. Kronfol, M. M., Dozmorov, M. G., Huang, R., et al. (2017). The role of epigenomics in personalized medicine. Expert review of precision medicine and drug development, 2(1), 33-45.
4. Van Eyk, J. E., & Snyder, M. P. (2018). Precision medicine: role of proteomics in changing clinical management and care. Journal of proteome research, 18(1), 1-6.
5. Clish, C. B. (2015). Metabolomics: an emerging but powerful tool for precision medicine. Molecular Case Studies, 1(1), a000588.
6. Shukla, S. K., Murali, N. S., & Brilliant, M. H. (2015). Personalized medicine going precise: from genomics to microbiomics. Trends in Molecular Medicine, 21(8), 461-462.
7. Gulilat, M., Lamb, T., Teft, W. A., et al. (2019). Targeted next generation sequencing as a tool for precision medicine. BMC medical genomics, 12, 1-17.
8. Kohler, I., Hankemeier, T., van der Graaf, P. H., et al. (2017). Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine. European journal of pharmaceutical sciences, 109, S15-S21.
9. Perkins, B. A., Caskey, C. T., Brar, P., et al. (2018). Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults. Proceedings of the National Academy of Sciences, 115(14), 3686-3691.
10. Chenoweth, M. J., Giacomini, K. M., Pirmohamed, M., et al. (2020). Global pharmacogenomics within precision medicine: challenges and opportunities. Clinical Pharmacology & Therapeutics, 107(1), 57-61.
11. Huang, S. (2014). The war on cancer: lessons from the war on terror. Frontiers in oncology, 4, 293.
12. Silvestri, G. A., & Rivera, M. P. (2005). Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest, 128(6), 3975-3984.
13. Chen, S., Liang, Y., Feng, Z., et al. (2019). Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis. BMC cancer, 19, 1-15.
14. Kiyotani, K., Toyoshima, Y., & Nakamura, Y. (2021). Personalized immunotherapy in cancer precision medicine. Cancer Biology & Medicine, 18(4), 955-965.
15. Dwivedi, S., Purohit, P., Misra, R., et al. (2017). Diseases and molecular diagnostics: a step closer to precision medicine. Indian Journal of Clinical Biochemistry, 32, 374-398.
16. Kelkar, S. S., & Reineke, T. M. (2011). Theranostics: combining imaging and therapy. Bioconjugate chemistry, 22(10), 1879-1903.
17. Weinshilboum, R. M., & Wang, L. (2017, November). Pharmacogenomics: precision medicine and drug response. In Mayo Clinic Proceedings (Vol. 92, No. 11, pp. 1711-1722). Elsevier.
18. Fahmi, A. M., Elewa, H., & El Jilany, I. (2022). Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. International Journal of Clinical Pharmacy, 44(3), 599-607.
19. Tesi, B., Boileau, C., Boycott, K. M., et al. (2023). Precision medicine in rare diseases: What is next?. Journal of internal medicine, 294(4), 397-412.
20. Ward, R. A., Aghaeepour, N., Bhattacharyya, R. P., et al. (2021, November). Harnessing the potential of multiomics studies for precision medicine in infectious disease. In Open Forum Infectious Diseases (Vol. 8, No. 11, p. ofab483). US: Oxford University Press.
21. Leopold, J. A., & Loscalzo, J. (2018). Emerging role of precision medicine in cardiovascular disease. Circulation research, 122(9), 1302-1315.
22. Naithani, N., Sinha, S., Misra, P., et al. (2021). Precision medicine: Concept and tools. medical journal armed forces india, 77(3), 249-257.
23. Noyes, J. D., Mordi, I. R., Doney, A. S., et al. (2021). Precision medicine and adverse drug reactions related to cardiovascular drugs. Diseases, 9(3), 55.
24. Ramaswami, R., Bayer, R., & Galea, S. (2018). Precision medicine from a public health perspective. Annual review of public health, 39(1), 153-168.
25. Von Groote, T., & Meersch-Dini, M. (2022). Biomarkers for the Prediction and Judgement of Sepsis and Sepsis Complications: A Step towards precision medicine?. Journal of Clinical Medicine, 11(19), 5782.
26. MacEachern, S. J., & Forkert, N. D. (2021). Machine learning for precision medicine. Genome, 64(4), 416-425.
27. Gray, M., Lagerberg, T., & Dombrádi, V. (2017). Equity and value in ‘precision medicine’. The New Bioethics, 23(1), 87-94.
28. Edwards, K. L., Korngiebel, D. M., Pfeifer, L., et al. (2016). Participant views on consent in cancer genetics research: preparing for the precision medicine era. Journal of Community Genetics, 7, 133-143.
29. Ahmed, Z. (2020). Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. Human genomics, 14(1), 35.
30. Sahu, M., Gupta, R., Ambasta, R. K., et al. (2022). Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis. Progress in molecular biology and translational science, 190(1), 57-100.
31. Di Meo, A., Bartlett, J., Cheng, Y., et al. (2017). Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Molecular cancer, 16, 1-14.
32. De Olazarra, A. S., & Wang, S. X. (2023). Advances in point-of-care genetic testing for personalized medicine applications. Biomicrofluidics, 17(3).